08/11/2024  17:31:57 Chg. -2.70 Volume Bid18:48:39 Demandez à18:48:39 Capitalisation boursière Dividende Y. Rapport P/E
263.10CHF -1.02% 1 Mio.
Chiffrre d'affaires: 265.14 Mio.
-Bid taille: 37 -Ask la taille: 232 243.32 Mrd.CHF 3.65% 18.27

Description de l'entreprise

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Conseil d'administration & Conseil de surveillance

PDG
Dr. Thomas Schinecker
Conseil d'administration
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Barbara Schädler, Boris L. Zaïtra
Conseil de surveillance
Dr. Severin Schwan, André Hoffmann, Anita Hauser, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Jörg Duschmalé
 

Données de l'entreprise

Nom: Roche Holding
Adresse: Grenzacherstraße 124,CH-4070 Basel
Téléphone: +41-61-688-1111
Fax: -
Courriel: basel.webmaster@roche.com
Internet: www.roche.com
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: 88.00%
IPO date: 03/04/1995

Relations avec les investisseurs

Nom: Bruno Eschli
Téléphone IR: +41 (61) 687 5284
IR-Fax: +41 (61) 691 0014
E-mail IR: bruno.eschli@roche.com

Principaux actionnaires

Group with pooled rights
 
64.97%
Autres
 
27.45%
Maja Oeri
 
7.58%